Page last updated: 2024-10-15

5-methyltetrahydrofolate

Description

5-methyltetrahydrofolate : A group of heterocyclic compounds based on the 5-methyl-5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid or L-glutamate units. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(6S)-5-methyltetrahydrofolic acid : A 5-methyltetrahydrofolic acid that has 6S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135483998
CHEBI ID182992
SCHEMBL ID16466806
MeSH IDM0047916
PubMed CID135398561
CHEMBL ID1231574
CHEBI ID15641
CHEBI ID136009
SCHEMBL ID79586
SCHEMBL ID12704423
MeSH IDM0047916

Synonyms (93)

Synonym
(2r)-2-[[4-[(2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
CHEBI:182992
n-(5-methyl-5,6,7,8-tetrahydropteroyl)-l-glutamic acid
5-methyltetrahydropteroylglutamate
5-methyltetrahydrofolate
5-METHYL-THF ,
5-methyl-tetrahydrofolate
n5-methyl-tetrahydrofolic acid
gtpl4684
(2r)-2-[(4-{[(2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
n5-methylfolate
SCHEMBL16466806
methyl-tetrahydrofolate
5-methyl tetrahydrofolate
5-methyl-5,6,7,8-tetrahydrofolate
n-(5-methyl-5,6,7,8-tetrahydropteroyl)-l-glutamate
n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-l-glutamic acid
n( 5)-methyltetrahydrofolate
n5-methyl-tetrahydrofolate
n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-l-glutamate
AC-7460
levomefolate
CHEMBL1231574
l-5-mthf
lmsr
5- methyltetrahydrofolate
CHEBI:15641 ,
n-[4-({[(6s)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
[(6s)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate
l-methylfolate
levomefolic acid
C00440
n-[4-({[(6s)-2-amino-4-hydroxy-5-methyl-5,6,7,8-tetrahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
THH ,
CHEBI:136009
(6s)-5-methyltetrahydrofolate
D09353
levomefolinic acid
31690-09-2
l-5-methyltetrahydrofolic acid
levomefolic acid (usan/inn)
(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
levomefolic acid [usan:inn]
l-5-methyltetrahydrofolate
n-(4-((((6s)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-l-glutamic acid
l-glutamic acid, n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, (s)-
8s95dh25xc ,
levomefolinic acid [usan]
unii-8s95dh25xc
bdbm50391007
AKOS016008744
HY-14781
CS-1067
levomefolate [vandf]
levomefolic acid [usan]
5-methyl-(6s)-tetrahydrofolic acid
l-glutamic acid, n-(4-((((6s)-2-amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6- pteridinyl)methyl)amino)benzoyl)-
levomefolic acid [inn]
n-(4-((((6s)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6- yl)methyl)amino)benzoyl)-l-glutamic acid
levomefolic acid [who-dd]
l-methylfolate [vandf]
(6s)-5-methyltetrahydrofolate [who-dd]
S6909
SCHEMBL79586
SCHEMBL12704423
l-glutamic acid, n-[4-[[(2-amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
ZNOVTXRBGFNYRX-STQMWFEESA-N
(6s)-5-methyltetrahydrofolic acid
AKOS025402272
DTXSID00185583
(2s)-2-{[4-({[(6s)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
J-018513
mfcd00870135
NCGC00485934-01
DB11256
(6s)-5-mthf
n-[4-[[[(6s)-2-amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-l-glutamic acid
n-{[4-({[(6s)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-l-glutamic acid
n-{[4-({[(6s)-2-amino-4-hydroxy-5-methyl-5,6,7,8-tetrahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-l-glutamic acid
(6s)-5-methyl-5,6,7,8-tetrahydrofolic acid
(see also l375720)
Q192553
AMY39069
(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
NCGC00378841-01
n-[4-[[[(6s)-2-amino-5-methyl-1,4,5,6,7,8-hexahydro-4-oxopteridine-6-yl]methyl]amino]benzoyl]-l-glutamic acid
levomefolicacid
EN300-19768229
levomefolic acid 100 microg/ml in acetonitrile:water
AS-0793
(2s)-2-{[4-({[(6s)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
L0335
(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioicacid

Toxicity

ExcerptReference
" A serious chronic side effect of the drug is its hepatotoxicity, which may culminate in hepatic cirrhosis and death."( Methotrexate hepatotoxicity.
Barak, AJ; Beckenhauer, HC; Tuma, DJ, 1984
)
" Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy."( Folate in depression: efficacy, safety, differences in formulations, and clinical issues.
Fava, M; Mischoulon, D, 2009
)
" Both formulae were well accepted without differences in tolerance or occurrence of adverse events."( Suitability and safety of L-5-methyltetrahydrofolate as a folate source in infant formula: A randomized-controlled trial.
Demmelmair, J; Gimpfl, M; Hecht, C; Koletzko, B; Lakovic, G; Roehle, R; Schoop, R; Sipka, L; Trisic, B; Troesch, B; Vusurovic, M; Zdjelar, S, 2019
)

Pharmacokinetics

The aim of the study was to explore the difference between MTHF CAC and the crystal form Ⅰ of 6S-5-methyltetrahydrofolate calcium salt (MTHF CA) The stability and pharmacokinetic behaviours were compared.

ExcerptReference
"After the use of d,1-folinic acid (d,1-CHO-THF), pharmacokinetic measurements should take into account 1-CHO-THF and its metabolite 1-methyltetrahydrofolic acid (1-CH3-THF) as well as d-CHO-THF."( Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid.
Kühl, M; Nüssler, V; Schalhorn, A; Stupp-Poutot, G, 1990
)
" Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45."( Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion.
Doroshow, JH; Newman, EM; Straw, JA, 1989
)
" In both studies the plasma half-life (t1/2) of the active isomer, L-formyltetrahydrofolate (CHO-THF), was only 32 to 35 minutes, whereas the inactive isomer, D-CHO-THF had a plasma t 1/2 of 352 to 485 minutes."( Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.
Doroshow, JH; Newman, EM; Straw, JA, 1987
)
" The elimination of MTHHF from the plasma followed a triexponential pattern, with a harmonic mean initial half-life of 20."( Clinical pharmacokinetics of 5-methyltetrahydrohomofolate.
Jiushi, L; Loo, TL; Lu, K; Savaraj, N, 1983
)
"To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients."( Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995
)
"This study highlights the efficacy of CP/FU/l FA in head and neck carcinoma and establishes the clinical importance of coupled FU/FA pharmacokinetics to predict pharmacodynamic variability."( Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995
)
"The pharmacokinetic profiles of folinic acid (FA) and its active metabolite, 5-methyltetrahydrofolic acid, were studied after oral administration of decreasing doses of calcium folinate during 37 courses of high and intermediate dose methotrexate treatment in 25 lymphoma patients."( Pharmacokinetics of folinic acid and 5-methyltetrahydrofolic metabolite after repeated oral administration of calcium folinate following methotrexate treatment.
Cano, J; Carcassonne, Y; Catalin, J; Lejeune, C; Monjanel-Mouterde, S; Payet, B; Tubiana-Mathieu, N, 1994
)
"The pharmacokinetic values of d,l-leucovorin and l-leucovorin were compared in eight healthy volunteers following oral administration of 25 mg d,l-leucovorin and 12."( Pharmacokinetic comparison of leucovorin and levoleucovorin.
De Gialluly, E; Hancock, C; Johnson, JB; Marquet, J; Tonelli, AP; Yacobi, A; Zittoun, J, 1993
)
" Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations."( A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996
)
" Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
" The aim of this study was to determine the pharmacokinetic properties of orally administered 6[R,S] 5-MTHF versus folic acid in cardiovascular patients with homozygosity for 677C --> T MTHFR."( Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease.
Aengevaeren, WR; Blom, HJ; Boers, GH; Verheugt, FW; Willems, FF, 2004
)
" The main pharmacokinetic parameters were calculated (Cmax, tmax, AUC)."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
"7 ng/mL), while tmax values were similar for the three folate forms."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
" In this study, folic acid (FA) was used as a model drug and aimed at investigating a reliable method for its detailed pharmacokinetic evaluations."( Folic acid and its metabolite codetermination for pharmacokinetics with circadian rhythms and evaluation of oral bioavailability.
Chen, W; Li, H; Meng, F; Shakya, S; Wang, C; Wu, L; Xu, J; Zhang, G; Zhang, J; Zhu, R, 2019
)
" To explore the difference between MTHF CAC and the crystal form Ⅰ of 6S-5-methyltetrahydrofolate calcium salt (MTHF CA) as well as an amorphous product of 6S-5-methyltetrahydrofolate glucosamine salt (MTHF GA), their stability and pharmacokinetic behaviours were compared."( Improved Stability of a Stable Crystal Form C of 6S-5-Methyltetrahydrofolate Calcium Salt, Method Development and Validation of an LC-MS/MS Method for Rat Pharmacokinetic Comparison.
Chen, H; Cheng, Y; Jia, Q; Lian, Z; Liu, K; Qiu, F, 2021
)

Compound-Compound Interactions

ExcerptReference
" Drugs were administered with a programmable-in-time pump by continuous infusion for 5 days."( Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994
)

Bioavailability

ExcerptReference
"The intestinal absorption and in vivo kinetics of (6S)-[3H]-5-methyl-tetrahydrofolate (5-methyl-H4folate), (6S)-[3H]-5-formyl-H4folate and [3H]folic acid were investigated to determine whether inherent differences exist in the overall bioavailability of these folates in rats."( Folic acid, 5-methyl-tetrahydrofolate and 5-formyl-tetrahydrofolate exhibit equivalent intestinal absorption, metabolism and in vivo kinetics in rats.
Bhandari, SD; Gregory, JF, 1992
)
" The effect of food on the bioavailability of folinic acid has not yet been studied, though it is most frequently administered orally."( Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
Borsi, JD; Moe, PJ; Romslo, I; Sagen, E, 1990
)
"The bioequivalence and bioavailability of oral and intravenous formulations of levoleucovorin and leucovorin were studied, and the absolute bioavailabilities of levoleucovorin and leucovorin tablet formulations were determined."( Bioequivalence of oral and injectable levoleucovorin and leucovorin.
DeVito, JM; Johnson, JB; Kozloski, GD; Tonelli, AP, 1993
)
" Thus, heat processing of milk not only reduced the amount of 5-CH3 THF significantly, but also changed the concentration of FBP and the folate-binding capacity of FBP, which may have implications on the bioavailability of milk folates."( Effect of milk processing on the concentration of folate-binding protein (FBP), folate-binding capacity and retention of 5-methyltetrahydrofolate.
Hansen, I; Holm, J; Høier-Madsen, M; Jägerstad, M; Wigertz, K, 1996
)
" The results suggest that tumors can compensate for low folate bioavailability by up-regulation of a second FR with slightly lower affinity for folic acid."( The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
Gates, SB; Grindey, GB; Habeck, LL; Mendelsohn, LG; Shackelford, KA; Shih, C; Worzalla, J, 1996
)
"We studied the effects of 5-MTHF on NO bioavailability in vivo in 10 patients with FH and 10 matched control subjects by venous occlusion plethysmography, using serotonin and nitroprusside as endothelium-dependent and -independent vasodilators."( 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.
Kastelein, JJ; Koomans, HA; Rabelink, TJ; van Dam, T; Verhaar, MC; Wever, RM, 1998
)
" The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
"The association of folates with the prevention of neural tube defects and reduced risk of other chronic diseases has stimulated interest in the development of techniques for the study of their bioavailability in humans."( Determination of 5-methyltetrahydrofolate (13C-labeled and unlabeled) in human plasma and urine by combined liquid chromatography mass spectrometry.
Finglas, PM; Hart, DJ; Mellon, F; Southon, S; Wolfe, CA; Wright, AJ, 2002
)
" Further research is needed to clarify the role of choline and methionine concentration and the importance of the reduced folate carrier and the folate receptor in determining the relative bioavailability of 5-MeTHF and FA with regard to genome stability."( A comparison of folic acid and 5-methyltetrahydrofolate for prevention of DNA damage and cell death in human lymphocytes in vitro.
Fenech, M; Wang, X, 2003
)
" Milk folate is entirely bound by an excess of folate-binding protein (FBP), prompting speculation that FBP may affect the bioavailability of the limited folate supply."( Dietary interactions influence the effects of bovine folate-binding protein on the bioavailability of tetrahydrofolates in rats.
Jones, ML; Nixon, PF; Treloar, T, 2003
)
" These data indicate that PteGlu and 5-formyltetrahydrofolic acid, which are thought to be well absorbed (about 90 %) at physiological doses, exhibit dramatically different rates and patterns of plasma response."( Single oral doses of 13C forms of pteroylmonoglutamic acid and 5-formyltetrahydrofolic acid elicit differences in short-term kinetics of labelled and unlabelled folates in plasma: potential problems in interpretation of folate bioavailability studies.
Dainty, JR; Finglas, PM; Gregory, JF; Hart, DJ; Southon, S; Wolfe, CA; Wright, AJ, 2003
)
" The effect of FBP on folate bioavailability has been widely discussed."( Bioaccessibility of folic acid and (6S)-5-methyltetrahydrofolate decreases after the addition of folate-binding protein to yogurt as studied in a dynamic in vitro gastrointestinal model.
Arkbåge, K; Havenaar, R; Verwei, M; Witthöft, C, 2003
)
" This could result in different bioavailability from folic acid- and 5-CH3-H4folate-fortified milk products."( The binding of folic acid and 5-methyltetrahydrofolate to folate-binding proteins during gastric passage differs in a dynamic in vitro gastrointestinal model.
Arkbåge, K; Groten, J; Havenaar, R; Mocking, H; Verwei, M, 2004
)
" All pharmacokinetic parameters demonstrate that the bioavailability of 5-MTHF is higher compared to folic acid."( Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease.
Aengevaeren, WR; Blom, HJ; Boers, GH; Verheugt, FW; Willems, FF, 2004
)
" Decreased nitric oxide (NO) bioavailability and increased vascular superoxide production in vascular disease states are due in part to endothelial NO synthase (eNOS) uncoupling related to deficiency of the eNOS cofactor tetrahydrobiopterin (BH4), but whether this mechanism is important in human atherosclerosis and represents a rational therapeutic target remains unclear."( 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling.
Antoniades, C; Cai, S; Channon, KM; de Bono, J; Lee, J; Leeson, P; Neubauer, S; Pillai, R; Ratnatunga, C; Refsum, H; Shirodaria, C; Warrick, N, 2006
)
"The bioavailability of dietary folate may be hampered by the need of the glutamate moieties to be deconjugated before absorption."( A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses.
Garbis, SD; Katan, MB; Kok, FJ; Lasaroms, JJ; Melse-Boonstra, A; van Breemen, RB; van Rhijn, JA; Verhoef, P; West, CE, 2006
)
"The objective was to estimate the bioavailability of polyglutamyl relative to that of monoglutamyl folic acid by using a sensitive stable-isotope approach that allowed for the administration of multiple low doses in humans."( A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses.
Garbis, SD; Katan, MB; Kok, FJ; Lasaroms, JJ; Melse-Boonstra, A; van Breemen, RB; van Rhijn, JA; Verhoef, P; West, CE, 2006
)
" After correction for this ratio, the estimated bioavailability of hexaglutamyl relative to that of monoglutamyl folic acid was >/=78%."( A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses.
Garbis, SD; Katan, MB; Kok, FJ; Lasaroms, JJ; Melse-Boonstra, A; van Breemen, RB; van Rhijn, JA; Verhoef, P; West, CE, 2006
)
"Multiple dosing of low amounts of labeled folic acid is a sensitive, accurate, and efficient method of measuring the relative bioavailability of folic acid compounds, provided that the administered doses can be reliably assessed."( A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses.
Garbis, SD; Katan, MB; Kok, FJ; Lasaroms, JJ; Melse-Boonstra, A; van Breemen, RB; van Rhijn, JA; Verhoef, P; West, CE, 2006
)
" Vascular superoxide and nitric oxide bioavailability were determined in segments of saphenous vein and internal mammary artery."( Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease.
Antoniades, C; Channon, KM; Francis, JM; Jackson, CE; Lee, J; Moat, SJ; Neubauer, S; Pillai, R; Ratnatunga, C; Refsum, H; Robson, MD; Shirodaria, C, 2007
)
" The impact of these changes on the bioavailability of folate in infants requires further exploration."( Unmetabolized folic acid and total folate concentrations in breast milk are unaffected by low-dose folate supplements.
Houghton, LA; O'Connor, DL; Yang, J, 2009
)
" We sought to distinguish the effects of plasma versus vascular tissue 5-MTHF and homocysteine on vascular redox and endothelial nitric oxide bioavailability in human vessels."( MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis.
Antoniades, C; Baarholm, OA; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Refsum, H; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T, 2009
)
" Nitric oxide bioavailability was evaluated by organ bath studies on saphenous vein rings."( MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis.
Antoniades, C; Baarholm, OA; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Refsum, H; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T, 2009
)
" Vascular 5-MTHF, rather than plasma or vascular homocysteine, is a key regulator of endothelial nitric oxide synthase coupling and nitric oxide bioavailability in human vessels, suggesting that plasma homocysteine is an indirect marker of 5-MTHF rather than a primary regulator of endothelial function."( MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis.
Antoniades, C; Baarholm, OA; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Refsum, H; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T, 2009
)
"Folic acid (pteroylmonoglutamic acid) has historically been used as the reference folate in human intervention studies assessing the relative bioavailability of dietary folate."( Comparison of (6 S)-5-methyltetrahydrofolic acid v. folic acid as the reference folate in longer-term human dietary intervention studies assessing the relative bioavailability of natural food folates: comparative changes in folate status following a 16-we
Finglas, PM; King, MJ; Powers, HJ; Wolfe, CA; Wright, AJ, 2010
)
" Studies comparing L-5-methyl-THF and folic acid have found that the two compounds have comparable physiological activity, bioavailability and absorption at equimolar doses."( Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics.
Bailey, L; Pietrzik, K; Shane, B, 2010
)
" Differences in stability and bioavailability of food folate compared to synthetic folic acid have been attributed to the presence of the polyglutamyl chain."( Influence of high-pressure processing on the profile of polyglutamyl 5-methyltetrahydrofolate in selected vegetables.
Balasubramaniam, VM; Riedl, KM; Schwartz, SJ; Somerville, J; Wang, C, 2011
)
" This has important implications for predicting apparent absorption of labeled folates in future bioavailability studies."( Estimation of the 5-methyltetrahydrofolate apparent volume of distribution in humans.
Barrett, DA; Brima, EI; Dainty, JR; Finglas, PM; King, MJ; Willis, G; Wright, AJ, 2012
)
" Compared with other forms of folates, 5-methyltetrahydrofolate (L-methylfolate or 5-MTHF) may represent a preferable treatment option for MDD given its greater bioavailability in patients with a genetic polymorphism, and the lower risk of specific side effects associated with folic acid."( Folates and S-adenosylmethionine for major depressive disorder.
Cassiello, CF; Iovieno, N; Papakostas, GI, 2012
)
"The bioavailability of EE and drospirenone was similar after administration of EE/drospirenone/levomefolate calcium and EE/drospirenone."( Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
Blode, H; Diefenbach, K; Eydeler, U; Richard, F; Rohde, B; Trummer, D; Wiesinger, H, 2012
)
" This is because the recommendations are often not followed or because the bioavailability of food folate is variable."( Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects?
Holzgreve, W; Obeid, R; Pietrzik, K, 2013
)
" After administration metafolin shows optimum absorption, comparable or higher bioavailability as well as physiological activity when compared to folic acid."( [Metafolin--alternative for folate deficiency supplementation in pregnant women].
Seremak-Mrozikiewicz, A, 2013
)
" Naturally occurring 5-MTHF has important advantages over synthetic folic acid - it is well absorbed even when gastrointestinal pH is altered and its bioavailability is not affected by metabolic defects."( Folate, folic acid and 5-methyltetrahydrofolate are not the same thing.
Panzavolta, G; Scaglione, F, 2014
)
"Different sources of folate may have different bioavailability and hence may impact the standard definition of folate equivalents."( Folate bioavailability from foods rich in folates assessed in a short term human study using stable isotope dilution assays.
Frank, T; Mönch, S; Netzel, G; Netzel, M; Ott, U; Rychlik, M, 2015
)
" The aim of this study was to compare the bioavailability of Quatrefolic®, a novel patented (6S)5-MTHF glucosamine salt, with (6S)5-MTHF calcium salt and folic acid in Sprague Dawley rats."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
"Quatrefolic® has demonstrated an enhanced oral bioavailability in comparison to other reduced folates and to folic acid in rats."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
"The aim of the study was to measure the relative bioavailability of labeled pteroylglutamic acid (13C5-PteGlu) from a pectin-coated fortified rice in vivo to measure any effect of the edible coating on folic acid bioavailability."( Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques.
Arcot, J; de Ambrosis, A; Haber, P; Paterson, J; Vishnumohan, S, 2017
)
"The bioavailability of folic acid in a pectin-coated rice premix was 68."( Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques.
Arcot, J; de Ambrosis, A; Haber, P; Paterson, J; Vishnumohan, S, 2017
)
"This study is the first demonstration of the bioavailability of folate in pectin-coated fortified rice in humans."( Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques.
Arcot, J; de Ambrosis, A; Haber, P; Paterson, J; Vishnumohan, S, 2017
)
"Generating bioavailability data from in vivo studies is time-consuming and expensive."( Simulation of Food Folate Digestion and Bioavailability of an Oxidation Product of 5-Methyltetrahydrofolate.
Ringling, C; Rychlik, M, 2017
)
"Homeostasis around vascular endothelium is a function of the equilibrium between the bioavailability of nitric oxide (NO) and oxidizing reactive oxygen species (ROS)."( Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy?
Ng, GA; Ng, LL; Yuyun, MF, 2018
)
" Thus, it is important to reliably determine the bioavailability of folates from various foods."( Quantitation of 5-methyltetraydrofolic acid in plasma for determination of folate status and clinical studies by stable isotope dilution assays.
Brandl, B; Kopp, M; Rychlik, M; Sam, L; Skurk, T; Striegel, L, 2019
)
" Hence, the pharmacokinetics of FA was conducted and showed that the administration of FA solution resulted in enhancing bioavailability of 5-methylTHF comparing with FA raw material suspension, whereas the free FA level in plasma was similar."( Folic acid and its metabolite codetermination for pharmacokinetics with circadian rhythms and evaluation of oral bioavailability.
Chen, W; Li, H; Meng, F; Shakya, S; Wang, C; Wu, L; Xu, J; Zhang, G; Zhang, J; Zhu, R, 2019
)
" The aim of this study was to evaluate the effects of 5-MTHF in combination with propranolol on HVPG and nitric oxide bioavailability markers in patients with cirrhosis and portal hypertension."( 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023
)
" HVPG and markers of nitric oxide bioavailability (BH4, ADMA and tHcy) were measured again at the end of treatment."( 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023
)
"Groups were similar in terms of baseline clinical and hemodynamic data and nitric oxide bioavailability markers."( 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023
)
" This effect appears to be mediated by improved nitric oxide bioavailability in the hepatic microcirculation."( 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)

Dosage Studied

ExcerptReference
" In the fibroblasts, MTX with thymidine + hypoxanthine rescue induced a marked increase in Hcy export, and the dose-response paralleled the cytotoxicity curves obtained for MTX without rescue."( Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture.
Christensen, B; Djurhuus, R; Refsum, H; Ueland, PM, 1991
)
" Pharmacokinetics and biochemical studies seem necessary to determine the optimal dosage and timing of 5-FU and folates."( Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985
)
" In the dose-response range studied there was no apparent affinity for methotrexate."( Purification and characterization of folate binding proteins from rat placenta.
da Costa, M; Rothenberg, SP, 1996
)
" Individualized 5-FU dosing to obtain higher 5-FU plasma concentrations may be indicated."( Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Athanasiadis, I; Dolan, ME; Haraf, DJ; Kies, MS; Kozloff, M; Malone, D; Mick, R; Ratain, MJ; Vokes, EE; Weichselbaum, RR, 1996
)
" In addition, 5-FU levels were detectable throughout the 28-day dosing period; however, there was no evidence of significant accumulation of uracil, tegafur, or 5-FU."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
" These data suggest that UFT/leucovorin should not be dosed simultaneously with food."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
" An liquid chromatography/mass spectrometry (LC/MS) procedure is described that has been validated for the determination of [13C]5-methyltetrahydropteroyl monoglutamic acid ([13C]5-CH3H4PteGlu) in plasma and urine, following oral dosing of volunteers with different labeled folates."( Determination of 5-methyltetrahydrofolate (13C-labeled and unlabeled) in human plasma and urine by combined liquid chromatography mass spectrometry.
Finglas, PM; Hart, DJ; Mellon, F; Southon, S; Wolfe, CA; Wright, AJ, 2002
)
" However, at 1 week after the administration of a single dosage 6[R,S] 5-MTHF, we detected 6[R] 5-MTHF following the administration of folic acid, indicating storage of this isomer in the body."( Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease.
Aengevaeren, WR; Blom, HJ; Boers, GH; Verheugt, FW; Willems, FF, 2004
)
"Multiple dosing of low amounts of labeled folic acid is a sensitive, accurate, and efficient method of measuring the relative bioavailability of folic acid compounds, provided that the administered doses can be reliably assessed."( A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses.
Garbis, SD; Katan, MB; Kok, FJ; Lasaroms, JJ; Melse-Boonstra, A; van Breemen, RB; van Rhijn, JA; Verhoef, P; West, CE, 2006
)
" Correcting the insufficiency by dosing folate along with the SSRI results in a significantly better antidepressant response."( The methylation, neurotransmitter, and antioxidant connections between folate and depression.
Miller, AL, 2008
)
" Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy."( Folate in depression: efficacy, safety, differences in formulations, and clinical issues.
Fava, M; Mischoulon, D, 2009
)
"Folate dose-response studies in women of childbearing age who consumed a folic acid (FA)-containing multivitamin in the era of FA fortification are lacking."( Folate-status response to a controlled folate intake in nonpregnant, pregnant, and lactating women.
Caudill, MA; Jiang, X; Malysheva, OV; Perry, CA; West, AA; Yan, J, 2012
)
" In the second trial, with 75 patients, the design was identical to the first, except that the l-methylfolate dosage was 15 mg/day during both 30-day periods."( L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
Alpert, JE; Baer, L; Barbee, JG; Bottiglieri, T; Clain, A; Dalton, ED; Etemad, B; Fava, M; Meisner, A; Mischoulon, D; Nelson, E; Papakostas, GI; Pencina, M; Rickels, K; Sacco, GR; Schoenfeld, D; Shelton, RC; Zajecka, JM; Zisook, S, 2012
)
" A common dosage of leucovorin in adjuvant and palliative settings is 60 mg/m(2)."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
" Further studies are needed to establish whether higher dosage yields a better treatment response."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
"CSF 5MTHF dosage should be considered in patients with mitochondrial diseases, primary brain calcifications and unexplained complex neurological disorders especially if associated with WMA, since folinic acid supplementation in patients with sCFD is frequently efficient."( Cerebral folate deficiency in adults: A heterogeneous potentially treatable condition.
Benoist, JF; Lubetzki, C; Masingue, M; Moussa, F; Nadjar, Y; Roze, E; Sedel, F, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
5-methyltetrahydrofolic acidA tetrahydrofolic acid that is 5,6,7,8-tetrahydrofolic acid substituted by a methyl group at position 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (24)

PathwayProteinsCompounds
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Folic acid network070
Selenium micronutrient network095
Vitamin B12 metabolism050
Folate metabolism156
Methionine de novo and salvage pathway148
Biochemical pathways: part I0466
Ethanol effects on histone modifications017
Folate metabolism ( Folate metabolism )2039
Methionine and Cysteine metabolism ( Methionine and Cysteine metabolism )2342
folate metabolism022
methionine biosynthesis020
superpathway of lysine, threonine and methionine biosynthesis I038
formylTHF biosynthesis II027
formylTHF biosynthesis I026
methionine biosynthesis I017
Folate-alcohol and cancer pathway012
Trans-sulfuration and one-carbon metabolism020
Folate-alcohol and cancer pathway hypotheses012
Trans-sulfuration pathway014
Trans-sulfuration, one-carbon metabolism and related pathways053
One-carbon metabolism and related pathways038
MTHFR deficiency1515
Disorders of folate metabolism and transport1827
Vitamin B12 disorders1313

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency2.51190.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Ki1.20000.50003.30008.2000AID681604
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki121.00000.84004.968210.0000AID679311
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Km126.00001.50004.34206.9000AID679013
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID681604TP_TRANSPORTER: inhibition of MTX uptake in OAT-K1-expressing MDCK cells2000The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3
Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.
AID679013TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from SD rat1998The American journal of physiology, 10, Volume: 275, Issue:4
Reduced folate derivatives are endogenous substrates for cMOAT in rats.
AID679311TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat1998The American journal of physiology, 10, Volume: 275, Issue:4
Reduced folate derivatives are endogenous substrates for cMOAT in rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (840)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990186 (22.14)18.7374
1990's171 (20.36)18.2507
2000's205 (24.40)29.6817
2010's212 (25.24)24.3611
2020's66 (7.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials100 (11.76%)5.53%
Trials0 (0.00%)5.53%
Reviews53 (6.24%)6.00%
Reviews0 (0.00%)6.00%
Case Studies37 (4.35%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other660 (77.65%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]